MEMORANDUM-DECISION AND ORDER
I. Introduction
Plaintiff pro se Louis Tatta (“Tatta”) brings this action pursuant to 42 U.S.C. § 1983. Tatta alleges that defendant Dr. Lester Wright (“Dr. Wright”), DOCS Chief Medical Officer, violated his constitutional rights under the First, Eighth, and Fourteenth Amendments. See Am. Compl.; Dkt. No 21. Dr. Wright’s motion for summary judgment was referred to Magistrate Judge David R. Homer for report and recommendation. 1 See Dkt. No. 23; see also 28 U.S.C. § 636(b)(1)(A), (B); N.D.N.Y.R. 72.3(c); Gen. Order No. 12, § D(1)(G). Judge Homer recommended that the complaint be dismissed in its entirety.
Pending are Tatta’s specific, timely objections to Judge Homer’s recommendation that the Eighth Amendment claim be dismissed, and that all of Tatta’s claims be dismissed under the alternate theory of qualified immunity. The court reviews these objections de novo and the remainder of the report for clear error. See Objection, Dkt. No. 29. Upon careful consideration of the arguments, the relevant parts of the record, the applicable law, and the additional reasons cited, the court adopts the Report-Recommendation.
II. Standard of Review
A party’s objection to the findings and recommendations of the Magistrate Judge must be filed within 10 days of receiving the Magistrate’s recommendation and order.
See Almonte v. N.Y. State Div. of Parole,
No. 9:04-CV-484,
Those recommendations and findings as to which the party has made timely, specific objection based on arguments raised before the Magistrate Judge must be reviewed de novo. Id. However, those recommendations and findings as to which the party has not made timely and/or specific objection are not entitled to any review, although the court may, in its discretion, elect to conduct a review nonetheless. Id. While a court may conduct a discretionary review under any standard it sees fit, this court has consistently applied a “clearly erroneous” standard. Id. Under *313 this standard a recommendation or finding of the Magistrate will be overturned only if “the court determines that there is a mistake of fact or law which is obvious and affects substantial rights.” Id. Objections based on arguments not raised as a matter of first impression before the Magistrate Judge are also not entitled to any review. Id. In such a situation the court may again elect to conduct a discretionary review, this time using a de novo standard as a matter of necessity, since the Magistrate has not had an opportunity to pass on the argument. Id.
III. Discussion
A. Equal Protection and First Amendment Claims
Judge Homer has recommended that Dr. Wright’s motion for summary judgment be granted on Tatta’s: (1) Equal Protection claim because it is based entirely on inadmissible hearsay, fails to allege different treatment between persons similarly situated, and puts forth no evidence of discriminatory animus; and (2) First Amendment claim because Tatta cannot “demonstrate he suffered any adverse action as a result of filing his grievances.” See R & R pgs. 318-20, Dkt. No. 28. Since Tatta has failed to object to Judge Homer’s recommendations on these claims in any form, he has procedurally defaulted. The court adopts Judge Homer’s recommendations of dismissal on the Equal Protection and First Amendment claims in their entirety as they are devoid of clear error.
B. Eighth Amendment Claim
Tatta has specifically and timely objected to Judge Homer’s recommendation that Wright’s motion for summary judgment on Tatta’s Eighth Amendment claim be granted. Thus, the court reviews the recommendation de novo.
An Eighth Amendment claim for denial of medical care under § 1983 requires that the prisoner put forth proof of “deliberate indifference to [his] serious medical needs” by the defendant.
Chance v. Armstrong,
Here, there is no dispute that Hepatitis C is a serious medical condition. Dr. Wright instead moves for summary judgment on the basis that Tatta has failed to show deliberate indifference to such condition. Tatta alleges that Dr. Wright failed to re-treat his Hepatitis C with Pegylated Interferon in combination with Ribavirin (“P Interferon”), for twenty-two months after Tatta was treated ineffectively with non-Pegylated Interferon with Ribavirin (“N Interferon”). See Comp. ¶¶ 1, 18, Dkt. No. 21. While retreatment with P Interferon was not FDA approved, Tatta asserts that “there was an exception to DOCS policy [that allowed approval of] medical treatments or re-treatments with non FDA approved drugs.” See Obj. ¶ 9, Dkt. No. 29. It is Dr. Wright’s failure to resort to such exception that Tatta claims exhibits deliberate indifference to his medical condition.
*314 This court agrees with Judge Homer’s finding that “[i]t was neither unreasonable nor indifferent for Dr. Wright to refuse a treatment not approved by the FDA.” See R & R pg. 818, Dkt. No. 28. While there may have been an exception in DOCS policy which would have allowed Dr. Wright to treat Tatta with P Interferon, it was available only “in rare cases” where there were “circumstances that permitted] exceptions to the general policy.” See Resp. in Opp. to MSJ, Affirmation pgs. A66-67; Dkt. No. 24. Special circumstances that would warrant such an exception were not presented to Dr. Wright when the initial request for retreatment with P Interferon was put before him. Id. Subsequently, when he became aware of such circumstances, Dr. Wright approved Tatta’s P Interferon retreatment. Id.
The decisions Dr. Wright made regarding treatment of Tatta’s condition did not exhibit a deliberate indifference to Tatta’s medical needs, but rather reasonable medical judgments based the information before him at the time. Viewing the facts in a light most favorable to Tatta, there is simply a dearth of any allegations of conduct that would rise to the level required to establish an Eighth Amendment violation.
C. Qualified Immunity
Because Tatta has specifically objected to Judge Homer’s finding that Dr. Wright was entitled to qualified immunity, the court reviews this finding de novo.
Qualified immunity protects government officials from civil liability provided “their conduct does not violate clearly established statutory or constitutional rights of which a reasonable person would have known.”
Harlow v. Fitzgerald,
IV. Conclusion
Having reviewed the Report-Recommendation, and Tatta’s specific objections de novo, the court adopts Judge Homer’s recommendation that the complaint be dismissed in its entirety for the reasons he articulated and for the additional reasons articulated by this court.
WHEREFORE, for the foregoing reasons, it is hereby
ORDERED that Judge Homer’s August 17, 2007 Report-Recommendation (Dkt. No. 28) is accepted and adopted in its entirety; and it is further
ORDERED that the Clerk of the Court enter judgment and close this case; and it is further
ORDERED that the Clerk of Court provide copies of this Order to the parties. IT IS SO ORDERED.
REPORT-RECOMMENDATION AND ORDER 1
Plaintiff pro se Louis Tatta (“Tatta”), an inmate in the custody of the New York State Department of Correctional Services (“DOCS”), brings this action pursuant to 42 U.S.C. § 1983 alleging that defendant Dr. Lester Wright (“Dr. Wright”), DOCS Chief Medical Officer, violated his constitutional rights under the First, Eighth, and Fourteenth Amendments. Am. Compl. (Docket No. 21). Presently pending is Dr. Wright’s motion for summary judgment *315 pursuant to Fed.R.Civ.P. 56. Docket No. 22. Tatta opposes the motion. Docket No. 24. For the following reasons, it is recommended that Dr. Wright’s motion be granted.
I. Background
The facts are presented in the light most favorable to Tatta as the non-moving party.
See Ertman v. United States,
At all relevant times, Tatta was an inmate in the custody of DOCS. In February 2000, Tatta was diagnosed with Hepatitis C. 2 See Tatta Dep. (Seaman Aff. (Docket No. 22), Ex. A) at 28. On July 25, 2000, Dr. Raelene Milicevic examined Tatta and recommended to Dr. Wright that Tatta begin treatment with a combination of nonPegylated Interferon with Ribavirin (“Rebetron”) to treat his Hepatitis C. See Wright Decl. (Docket No. 22) at ¶ 28 & Ex. C. Later that same day, Dr. Wright approved Dr. Milicevic’s request to treat Tat-ta with Rebetron. Wright Decl. at ¶29. On December 4, 2000, Tatta was examined via telemed by Dr. Rogers, a gastroenterologist. See Seaman Aff., Ex. C at 9. Dr. Rogers discussed treating Tatta with Rebetron, but that Tatta preferred to wait to see if the Food and Drug Administration (“FDA”) would approve Pegylated Interferon 3 for treating Hepatitis. Id. However, in late December 2000, Tatta consented to treatment with non-Pegylated Interferon with Ribavirin and on or about January 6, 2001, Tatta began receiving treatment. See Seaman Aff., Ex. C at 1-2, 10, 36. The full course of treatment with nonPegylated Interferon with Ribavirin is administered over forty-eight weeks. See Wright Decl. at ¶ 24.
On or about January 19, 2001, the FDA approved the use of Pegylated Interferon for naive patients, ie., patients whose Hepatitis had not previously been treated with Interferon. See Seaman Aff., Ex. B at 1-4. On July 9, 2001, Dr. Rogers examined Tatta and noted that even though Tatta had been treated with Rebetron for the past six months, the “rebetron has failed” and should be discontinued. Seaman Aff., Ex. C at 14. Dr. Rogers also noted that Tatta should return in six months for consideration of newer medication to treat his Hepatitis. Id. Per Dr. Rogers’ request, Tatta’s treatment with Rebetron was discontinued on July 12, 2001. See Seaman Aff., Ex. C at 3, 14. On or about August 7, 2001, the FDA approved the use of Pegylated Interferon with Ribavirin for naive patients. See Seaman Aff., Ex. B at 5-7; see also Wright Decl. at ¶ 10,18-19.
On January 22, 2002, Tatta wrote Dr. Wright a letter seeking the status of his follow-up examination with Dr. Rogers. See Wright Decl., Ex. D; see also Am. Compl. at ¶ 2. Tatta also requested that if Pegylated Interferon with Ribavirin was not currently available to DOCS inmates, he be treated with Pegylated Interferon “as a maintenance therapy.” Id. Dr. Wright forwarded Tatta’s letter to Dr. Marc Stern for investigation and handling. See Wright Decl. at ¶¶ 31-32. On September 19, 2002, Dr. Stern responded to Tat-ta’s January 2002 letter, noting that the re-treatment of patients such as Tatta with Pegylated Interferon was still deemed experimental by the FDA and, thus, would not be approved by DOCS. See Wright Deck, Ex. E. During this time, Tatta was *316 examined by Dr. Rogers, who noted that “[i]f approved by DOC[S],” Tatta may be retreated with Pegylated Interferon in combination with Ribavirin. See Seaman Aff., Ex. C at 15.
On April 28, 2002, Tatta was examined by Dr. Douglas Fish, an infectious disease specialist, who agreed with Dr. Rogers’ recommendation for retreating Tatta with Pegylated Interferon in combination with Ribavirin. See Seaman Aff., Ex. C at 8, 16. Shortly thereafter, Dr. Mikhail Gus-man, a physician at Eastern Correctional Facility (“Eastern”), contacted Dr. Wright to request approval to retreat Tatta’s Hepatitis C with the combination therapy of Pegylated-Interferon with Ribavirin. See Wright Deck, Ex. H at 1-3; see also Am. Compl. at ¶ 4. Dr. Wright informed Dr. Gusman that Pegylated Interferon was not approved by the FDA for retreatment of Hepatitis C. See Wright Deck, Ex. H at 3-4.
On August 28, 2003, Dr. Carl Koenigsmann, a DOCS Regional Director, sent an email to Dr. Milicevic at Eastern in response to a letter from Tatta requesting re-treatment of his Hepatitis. See Seaman Aff., Ex. C at 37. Dr. Koenigsmann noted that based on the new practice guidelines, Tatta’s condition may be treatable with combination therapy of Pegylated Interferon with Ribavirin. Id. On September 18, 2003, Dr. Kathpalia, a psychiatrist, approved the recommended combination therapy of Pegylated Interferon with Ribavirin. See Seaman Deck, Ex. C at 17. On December 16, 2003, Dr. Milicevic submitted a request to Dr. Wright seeking approval to retreat Tatta’s Hepatitis C with Pegylated Interferon in combination with Ribavirin. See Wright Deck, Ex. K. Shortly thereafter, Dr. Wright approved the request. Id. On January 6, 2004, Tat-ta’s retreatment began with the combination therapy of Pegylated Interferon and Ribavirin. See Seaman Aff., Ex. C at 7; see also Am. Compl. at ¶¶ 18-19. This action followed.
II. Discussion
Tatta asserts three causes of action against Dr. Wright alleging that he was (1) deliberately indifferent to his serious medical needs in violation of the Eighth Amendment, (2) discriminated against him because of his HIV status in violation of the Fourteenth Amendment, and (3) retaliated against him for filing grievances in violation of the First Amendment. See Am. Compl. at 5. Dr. Wright seeks judgment on all claims.
A. Standard
A motion for summary judgment may be granted if there is no genuine issue as to any material fact if supported by affidavits or other suitable evidence and the moving party is entitled to judgment as a matter of law. The moving party has the burden to show the absence of disputed material facts by informing the court of portions of pleadings, depositions, and affidavits which support the motion. Fed.R.Civ.P. 56(c);
Celotex Corp. v. Catrett,
The party opposing the motion must set forth facts showing that there is a genuine issue for trial. The non-moving party must do more than merely show that there is some doubt or speculation as to the true nature of the facts.
Matsushita Elec. Indus. Co. v. Zenith Radio Corp.,
B. Eighth Amendment
Tatta contends that Dr. Wright intentionally delayed approval of his retreatment of Hepatitis C for twenty-two months. See Am. Compl. at 5; see also id. at ¶ 18. Liberally construed, Tatta also contends that “[Dr. Wright’s] medical staff at Eastern ... intentionally failed on numerous occasions to provide [Tatta] with his medications in a timely fashion.” See Am. Compl. at 5.
A prisoner advancing an Eighth Amendment claim for denial of medical care must allege and prove deliberate indifference to a serious medical need.
Wilson v. Seiter,
A serious medical need is “ ‘one that has been diagnosed by a physician as requiring treatment, or one that is so obvious that even a layperson would easily recognize the necessity for a doctor’s attention.’ ”
Camberos v. Branstad,
Dr. Wright contends, however, that Tatta has failed to meet the deliberate indifference requirement, of his claim. Deliberate indifference requires the prisoner to prove that the prison official knew of and disregarded the prisoner’s serious medical needs.
Id.
at 702. Mere disagreement over proper treatment does not create a constitutional claim as long as the treatment was adequate.
Id.
at 703. Allegations of negligence or malpractice do not
*318
constitute deliberate indifference unless the malpractice involved culpable recklessness.
Hathaway v. Coughlin,
Here, there is no evidence that the medical treatment Tatta received between Dr. Wright’s initial denial of Tatta’s April 2002 request to be retreated with Pegylated Interferon in combination with Ribavirin and his subsequent approval of Tatta’s request in December 2003 was inadequate. Further, Dr. Wright has repeatedly stated that he initially refused to re-treat Tatta with Pegylated-Interferon with Ribavirin because, even though recommended by Drs. Fish and Rogers, the treatment had yet to gain FDA approval.
See
Wright Decl. at ¶¶ 18, 35-39. It was neither unreasonable nor indifferent for Dr. Wright to refuse a treatment not approved by the FDA. Thus, Tatta has failed to demonstrate that Dr. Wright was deliberately indifferent to his serious medical needs.
See United States ex rel. Hyde v. McGinnis,
As to Tatta’s allegation that Eastern’s medical department intentionally failed to provide him with his medications in a timely fashion, this contention is without merit. Tatta contends that he was temporarily denied the following medications: Pegylated-Interferon, Glucerna (a dietary supplement), and Epogen (for anemia).
See
Seaman Aff., Ex. B at 8-24. However, it is undisputed that Tatta’s temporary delays in receiving his medications did not seriously affect his health.
5
See
Def. Statement of Material Facts (Docket No. 22) at ¶¶ 55, 61; PI. Mem. of Law at ¶¶ 18, 21. Further, Tatta offers only vague, conclusory allegations to show that the temporary delays in administering his medications presented a substantial risk of harm. Thus, Tatta has failed to offer any evidence to demonstrate that the temporary delay in receiving his medications caused any serious harm, much less that Dr. Wright was in any way deliberately indifferent to Tatta’s serious medical needs.
See Pierre v. County of Broome,
No. Civ. 05-332(TJM),
Therefore, it is recommended that Dr. Wright’s motion on this ground be granted.
C. Equal Protection
Liberally ' construed, Tatta’s second cause of action alleges that Dr. Wright violated his equal protection rights under the Fourteenth Amendment when Tatta was treated differently from another inmate, Robert Wooley, whom Tatta contends was accorded the treatment sought by Tatta. See Am. Compl. at ¶ 5, 10-13.
The Fourteenth Amendment’s Equal Protection Clause mandates equal treatment under the law. Essential to
*319
that protection is the guarantee that similarly situated persons be treated equally.
City of Cleburne, Tex. v. Cleburne Living Ctr.,
Tatta’s equal protection claim fails for at least three reasons. First, The evidence offered by Tatta to support this claim consists entirely of inadmissible hearsay information concerning Wooley’s medical condition and treatment.
See
Am. Compl. at ¶¶ 11-13. Under Rule 56(e), the party opposing a motion for summary judgment must raise a material question of fact through affidavits “made” on personal knowledge.” A statement, as here, asserting the existence of facts not personally known to the declarant may not be considered.
See Patterson v. County of Oneida, N.Y.,
Second, even if Tatta’s statements about Wooley’s condition and treatment are considered, there is insufficient evidence offered by Tatta to determine that Tatta and Wooley were similarly situated. For example, it appears from the amended complaint that Tatta never responded medically to the treatment he received while Wooley responded medically for a period of one year before relapsing. Am. Compl. at ¶ 12. The undisputed fact that Wooley responded medically to the initial treatment while Tatta did not supports Dr. Wright’s differentiated treatment of the two inmates and defeats Tatta’s claim that the two inmates were similarly situated. Tatta’s equal protection claim, therefore, also fails for this reason.
Finally, even assuming that Tat-ta’s hearsay assertions should be considered and credited, and assuming that Tat-ta and Wooley were similarly situated but treated differently, there is no evidence that Dr. Wright’s different treatment of Tatta was motivated by discriminatory animus.
See Douglas v. Stanwick,
Therefore, it is recommended that Dr. Wright’s motion on this ground be granted.
*320 D. Retaliation
In his third cause of action, Tatta contends that “in retaliation for plaintiffs filings of numerous grievances against the medical department, defendant’s medical staff at Eastern ... intentionally failed on numerous occasions to provide the plaintiff with his medications in a timely fashion as prescribed by the facility doctor .... ” Am. Compl. at 5.
In order to prevail on a retaliation claim, a plaintiff must first assert that his conduct was constitutionally protected and that this conduct was a “substantial factor” that caused the adverse action against plaintiff.
Mt. Healthy City Sch. Dist. Bd. of Educ. v. Doyle,
Here, Tatta’s filing of grievances were clearly assertions of a constitutional right protected by the First Amendment.
See Graham v. Henderson,
Therefore, Dr. Wright’s motion for summary judgment on this ground should be granted.
E. Qualified Immunity
Dr. Wright also contends that he is entitled to qualified immunity. Qualified immunity generally protects governmental officials from civil liability insofar as their conduct does not violate clearly established constitutional law of which a reasonable person would have known.
Harlow v. Fitzgerald,
Therefore, in the alternative, it is recommended that Dr. Wright’s motion on this ground be granted.
III. Conclusion
For the reasons stated above, it is hereby:
RECOMMENDED that Dr. Wright’s motion for summary judgment (Docket No. 22) be GRANTED and the case be terminated.
Pursuant to 28 U.S.C. § 636(b)(1), the parties may lodge written objections to the foregoing report. Such objections shall be filed with the Clerk of the Court. FAILURE TO OBJECT TO THIS REPORT WITHIN TEN DAYS WILL PRECLUDE APPELLATE REVIEW.
Roldan v. Racette, 984
F.2d 85, 89 (2d Cir. 1993);
Small v. Sec’y of HHS,
Notes
. The Clerk is directed to append Judge Homer’s Report-Recommendation to this decision, and familiarity is presumed.
. This matter was referred to the undersigned for report and recommendation pursuant to 28 U.S.C. § 636(b) and N.D.N.Y.L.R. 72.3(c).
. Hepatitis C is “a chronic viral liver disease that can increase the risk of liver cancer and can lead to inflammation, scarring, and cirrhosis of the liver. Cirrhosis ultimately can lead to liver failure and death.”
Pabon v. Wright,
. "Pegylated Interferon tends to be metabolized more slowly than non-Pegylated Interferon. As a result, it tends to remain in the body for longer periods of time.” Wright Decl. at ¶ 20.
. In his memorandum of law, Dr. Wright does not appear to dispute the contention that Tatta's Hepatitis C constitutes a serious medical need.- See Def. Mem. of Law (Docket No. 22) at 2-7.
. Although Tatta contends that the delays in distributing Glucerna caused him to feel fatigued and weak, these temporary conditions hardly constitute a serious medical need. See PI. Reply Statement of Facts (Docket No. 24) at V 21.
. Moreover, Tatta has failed to demonstrate that Dr. Wright was personally involved in the temporary denial of medications. There is no evidence beyond Tatta’s conclusory allegations that Dr. Wright participated in the temporary denial of medications, created a policy which allowed the temporary denial of medications to continue, or was grossly negligent in managing the medical staff at Eastern.
